Anzeige
Mehr »
Sonntag, 20.09.2026 - Börsentäglich über 12.000 News
Breaking News: NurExone im Vollgas-Modus!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
OH

WKN: A42KL5 | ISIN: KYG6S38M1318 | Ticker-Symbol:
NASDAQ
18.09.26 | 18:04
2,360 US-Dollar
-1,26 % -0,030
Branche
Immobilien
Aktienmarkt
ASIEN
1-Jahres-Chart
OHMYHOME LIMITED Chart 1 Jahr
5-Tage-Chart
OHMYHOME LIMITED 5-Tage-Chart

Aktueller Chart OHMYHOME Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
OHMYHOME LIMITED-Investoren interessieren sich auch für diese Wertpapiere
Paladin Envirotech: Paladin Deepens Allied Supply Chain Footprint with South Korea Strategic Initiative and Netherlands Expansion, Advances Ex-China Rare Earth Recovery New initiative with Daeheung M&T and expansion in the Netherlands mark $85 million in global investment to date, accelerating deployment of RECapture and Critical Minerals Recycling, Inc. technology...
► Artikel lesen
XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 10.04.2026The following instruments on Boerse Frankfurt do have their last trading day on 10.04.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 10.04.2026.ISIN NameAU000000ICI5...
► Artikel lesen
Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatesSite Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from...
► Artikel lesen
Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual MeetingApproximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase...
► Artikel lesen
Cellectar Biosciences, Inc.: Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesAnnounced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) Completed Financing of up to $140 Million to Support Initiation of Confirmatory...
► Artikel lesen